PROCEPT BioRobotics (PRCT) said Monday that an independent trial showed its aquablation therapy provided similar symptom relief, with superior ejaculatory function and continence preservation compared to laser enucleation for treating large prostates.
The company said the study, which treated 186 men, showed positive results for the three-month primary safety and efficacy endpoints, with long-term follow-up planned for up to five years.
The aquablation therapy arm also reported a 0% transfusion rate, highlighting the therapy's safety and effectiveness in minimizing bleeding risks, it added.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。